Show simple item record

dc.contributor.authorWelch, Richard
dc.contributor.authorJames, Roger D
dc.contributor.authorWilkinson, Peter M
dc.contributor.authorBelli, F
dc.contributor.authorCowan, Richard A
dc.date.accessioned2010-05-07T10:49:25Z
dc.date.available2010-05-07T10:49:25Z
dc.date.issued1995
dc.identifier.citationRecombinant human erythropoietin and platinum-based chemotherapy in advanced ovarian cancer., 1 (4):261-6 Cancer J Sci Amen
dc.identifier.issn1081-4442
dc.identifier.pmid9166486
dc.identifier.urihttp://hdl.handle.net/10541/98159
dc.description.abstractPURPOSE: Patients with ovarian cancer often experience dose-limiting myelotoxicity, nephrotoxicity and anemia following treatment with platinum-based chemotherapy. PATIENTS AND METHODS: To investigate the ability of recombinant human erythropoietin (epoetin alfa) to prevent the development of anemia, 30 patients with advanced ovarian carcinoma receiving cisplatin or carboplatin were randomly assigned to treatment with subcutaneous epoetin alfa 300 IU/kg three times a week in addition to conventional supportive treatment, or conventional supportive treatment alone, for up to six chemotherapy cycles. The dose of epoetin alfa was reduced if hemoglobin concentration exceeded 15 g/dL. RESULTS: A highly significant difference in mean hemoglobin concentrations was observed between the two groups during the first cycle of chemotherapy due to a significant decrease in mean hemoglobin concentration in the control group. A maximal difference of 3.4 g/dL was achieved during cycle three. Fewer patients required blood or platelet transfusions in the epoetin alfa-treated group, although the difference was not significant compared to the control group. Epoetin alfa was well tolerated. CONCLUSION: Epoetin alfa appears to be effective and well tolerated in preventing hemoglobin decline in patients undergoing aggressive cyclic platinum-based chemotherapy for advanced ovarian carcinoma.
dc.language.isoenen
dc.subjectAnaemiaen
dc.subjectHaematinicsen
dc.subjectHaemoglobinsen
dc.subjectGlandular and Epithelial Canceren
dc.subjectOvarian Canceren
dc.subject.meshAdolescent
dc.subject.meshAdult
dc.subject.meshAged
dc.subject.meshAnemia
dc.subject.meshAntineoplastic Combined Chemotherapy Protocols
dc.subject.meshBlood Transfusion
dc.subject.meshCarboplatin
dc.subject.meshCisplatin
dc.subject.meshEpoetin Alfa
dc.subject.meshFemale
dc.subject.meshHematinics
dc.subject.meshHemoglobins
dc.subject.meshHumans
dc.subject.meshMale
dc.subject.meshMiddle Aged
dc.subject.meshNeoplasms, Glandular and Epithelial
dc.subject.meshOvarian Neoplasms
dc.subject.meshQuality of Life
dc.subject.meshTreatment Outcome
dc.titleRecombinant human erythropoietin and platinum-based chemotherapy in advanced ovarian cancer.en
dc.typeArticleen
dc.contributor.departmentDepartment of Clinical Oncology, Christie Hospital, Manchester, United Kingdom.en
dc.identifier.journalThe Cancer Journal from Scientific Americanen
html.description.abstractPURPOSE: Patients with ovarian cancer often experience dose-limiting myelotoxicity, nephrotoxicity and anemia following treatment with platinum-based chemotherapy. PATIENTS AND METHODS: To investigate the ability of recombinant human erythropoietin (epoetin alfa) to prevent the development of anemia, 30 patients with advanced ovarian carcinoma receiving cisplatin or carboplatin were randomly assigned to treatment with subcutaneous epoetin alfa 300 IU/kg three times a week in addition to conventional supportive treatment, or conventional supportive treatment alone, for up to six chemotherapy cycles. The dose of epoetin alfa was reduced if hemoglobin concentration exceeded 15 g/dL. RESULTS: A highly significant difference in mean hemoglobin concentrations was observed between the two groups during the first cycle of chemotherapy due to a significant decrease in mean hemoglobin concentration in the control group. A maximal difference of 3.4 g/dL was achieved during cycle three. Fewer patients required blood or platelet transfusions in the epoetin alfa-treated group, although the difference was not significant compared to the control group. Epoetin alfa was well tolerated. CONCLUSION: Epoetin alfa appears to be effective and well tolerated in preventing hemoglobin decline in patients undergoing aggressive cyclic platinum-based chemotherapy for advanced ovarian carcinoma.


This item appears in the following Collection(s)

Show simple item record